Autism

Autism represents a large patient population with unmet medical needs.  According to the latest study by the Centers for Disease Control and Prevention (CDC), autism affects approximately one in 110 children.  Some 70% of children with autism could potentially benefit from Curemark’s enzyme replacement therapy, one of first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

Curemark has identified a series of biomarkers that determine which children with autism and Pervasive Developmental Disorder (PDD) may have digestive deficiencies underlying or as a major component of their disease.  Research by Dr. Joan Fallon, Curemark’s CEO and founder, showed enzyme deficiencies in children with autism, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  Curemark is progressing with Phase III clinical trials for its CM-AT autism treatment, which has been granted fast track status by the FDA.